{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Randomized+Controlled+Study&page=67", "query": { "condition": "Randomized Controlled Study", "page": 67 }, "page_size": 10 }, "pagination": { "page": 67, "page_size": 10, "total_count": 15138, "total_pages": 1514, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Randomized+Controlled+Study&page=68&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Randomized+Controlled+Study&page=66&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-29T05:31:42.103Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00257608", "title": "A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "bevacizumab", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "erlotinib HCl", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1145, "start_date": "2006-01", "completion_date": "2014-11", "has_results": true, "last_update_posted_date": "2016-04-18", "last_synced_at": "2026-10-29T05:31:42.103Z", "location_count": 177, "location_summary": "Mobile, Alabama • Fort Smith, Arizona • Scottsdale, Arizona + 160 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Fort Smith", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Alhambra", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00257608" }, { "nct_id": "NCT04980391", "title": "A Study on the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine, in High Risk Pregnant Women Aged 15 to 49 Years and Infants Born to the Vaccinated Mothers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Respiratory Syncytial Virus Infections" ], "interventions": [ { "name": "RSV MAT", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "15 Years", "maximum_age": "49 Years", "sex": "FEMALE", "summary": "15 Years to 49 Years · Female only" }, "enrollment_count": 384, "start_date": "2021-08-03", "completion_date": "2023-05-30", "has_results": true, "last_update_posted_date": "2025-04-20", "last_synced_at": "2026-10-29T05:31:42.103Z", "location_count": 16, "location_summary": "Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 13 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Covington", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04980391" }, { "nct_id": "NCT05306574", "title": "A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Systemic Lupus Erythematosus" ], "interventions": [ { "name": "Telitacicept", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Vor Biopharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "12 Years to 70 Years" }, "enrollment_count": 91, "start_date": "2022-06-20", "completion_date": "2025-01-06", "has_results": false, "last_update_posted_date": "2026-01-09", "last_synced_at": "2026-10-29T05:31:42.103Z", "location_count": 12, "location_summary": "Anniston, Alabama • Mission Hills, California • Orange, California + 9 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Mission Hills", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Thousand Oaks", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05306574" }, { "nct_id": "NCT02920918", "title": "Treatment of Diabetes in Patients With Systolic Heart Failure", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Heart Failure, Systolic", "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Canagliflozin", "type": "DRUG" }, { "name": "Sitagliptin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Virginia Commonwealth University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2016-10", "completion_date": "2018-09", "has_results": true, "last_update_posted_date": "2019-10-29", "last_synced_at": "2026-10-29T05:31:42.103Z", "location_count": 1, "location_summary": "Richmond, Virginia", "locations": [ { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02920918" }, { "nct_id": "NCT04770220", "title": "An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Early Alzheimer's Disease" ], "interventions": [ { "name": "Experimental: ALZ-801", "type": "DRUG" }, { "name": "Placebo Comparator: Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alzheon Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "50 Years to 80 Years" }, "enrollment_count": 325, "start_date": "2021-05-19", "completion_date": "2024-07-29", "has_results": true, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-29T05:31:42.103Z", "location_count": 55, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 50 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Costa Mesa", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04770220" }, { "nct_id": "NCT00429676", "title": "Pilot Study of Haloperidol to Treat Critical Illness Delirium", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Delirium", "Critical Illness" ], "interventions": [ { "name": "Haloperidol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2005-12", "completion_date": "2007-09", "has_results": false, "last_update_posted_date": "2012-11-14", "last_synced_at": "2026-10-29T05:31:42.103Z", "location_count": 1, "location_summary": "Denver, Colorado", "locations": [ { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00429676" }, { "nct_id": "NCT01176097", "title": "To Assess Safety, Tolerability, Pharmacokinetics/Pharmacodynamics and the Effect of Fasting After Single Oral Doses of AZD5658 in Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "AZD5658", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "20 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "20 Years to 65 Years" }, "enrollment_count": 24, "start_date": "2010-07", "completion_date": "2011-02", "has_results": false, "last_update_posted_date": "2012-02-02", "last_synced_at": "2026-10-29T05:31:42.103Z", "location_count": 1, "location_summary": "Chula Vista, California", "locations": [ { "city": "Chula Vista", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01176097" }, { "nct_id": "NCT03879408", "title": "Naproxen Sodium/Acetaminophen Proof of Concept Dosing Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pain" ], "interventions": [ { "name": "440 mg naproxen sodium with 1000 mg acetaminophen", "type": "DRUG" }, { "name": "220 mg naproxen sodium with 650 mg acetaminophen", "type": "DRUG" }, { "name": "10 mg hydrocodone + 650 mg acetaminophen", "type": "DRUG" }, { "name": "440 mg naproxen sodium", "type": "DRUG" }, { "name": "Placebo tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "17 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "17 Years to 50 Years" }, "enrollment_count": 290, "start_date": "2019-05-28", "completion_date": "2019-11-13", "has_results": true, "last_update_posted_date": "2022-12-05", "last_synced_at": "2026-10-29T05:31:42.103Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT03879408" }, { "nct_id": "NCT01074008", "title": "A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C", "HCV", "Chronic Hepatitis C Infection", "Hepatitis C Genotype 1" ], "interventions": [ { "name": "ABT-450", "type": "DRUG" }, { "name": "ABT-072", "type": "DRUG" }, { "name": "ABT-333", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "Peginterferon alpha-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "AbbVie (prior sponsor, Abbott)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 74, "start_date": "2010-03", "completion_date": "2012-01", "has_results": true, "last_update_posted_date": "2015-01-08", "last_synced_at": "2026-10-29T05:31:42.103Z", "location_count": 25, "location_summary": "Phoenix, Arizona • Anaheim, California • La Jolla, California + 19 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01074008" }, { "nct_id": "NCT04639050", "title": "Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Alzheimers Disease" ], "interventions": [ { "name": "RO7126209", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "50 Years to 85 Years" }, "enrollment_count": 241, "start_date": "2021-03-15", "completion_date": "2027-07-31", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-29T05:31:42.103Z", "location_count": 15, "location_summary": "Atlantis, Florida • Clermont, Florida • Lady Lake, Florida + 12 more", "locations": [ { "city": "Atlantis", "state": "Florida" }, { "city": "Clermont", "state": "Florida" }, { "city": "Lady Lake", "state": "Florida" }, { "city": "Maitland", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04639050" } ] }